pharma · Metastatic Colorectal Cancer · Duchenne Muscular Dystrophy · SMMT
Summit Therapeutics
Summit Therapeutics is a pharma organization headquartered in Miami, USA. It trades on NYSE under ticker SMMT. Primary therapeutic focus areas include Metastatic Colorectal Cancer, Duchenne Muscular Dystrophy, Non-Small
Company details
- Status
- Public
- HQ
- 601 Brickell Key Dr, Suite 1000, Miami, Florida 33131, US
- Founded
- 2003
- Employees
- 367
- Programs
- 41
- Drugs
- 32
- Patents
- 20
Quick answer
Summit Therapeutics is a pharma organization headquartered in Miami, USA. It trades on NYSE under ticker SMMT. Primary therapeutic focus areas include Metastatic Colorectal Cancer, Duchenne Muscular Dystrophy, Non-Small Cell Lung Cancer, Clostridium Difficile Infection, Metastatic Non-small Cell Lung Cancer. NovaPharmaNews links 41 clinical program(s), 0 drug profile(s), and 20 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (23), phase 3 (9), phase 1 (4).
Company snapshot
Summit Mission Statement: To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life,
- 41 active pipeline program(s) linked via ClinicalTrials.gov.
- 20 US patent(s) indexed to this assignee profile.
- 41 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Summit Therapeutics. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
- trial_data
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
- approval
Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation
- deal
ASCO Summit: Ivonescimab's China Lung Data Shows Promise, But Global Validation Remains Key
Recent coverage
ASCO Summit: Ivonescimab's China Lung Data Shows Promise, But Global Validation Remains Key
Summit Therapeutics' ivonescimab demonstrated a significant survival benefit in a Chinese lung cancer trial presented at ASCO, yet analysts caution that replicating these results in a broader, global population is crucial for its market potential against established therapies like Keytruda.
Fulcrum Therapeutics Stock Plummets 54% Following Sickle Cell Drug Discontinuation
Fulcrum Therapeutics' stock experienced a significant 54% drop following the discontinuation of its sickle cell disease drug, citing regulatory hurdles. This event highlights potential challenges in clinical trial design for the indication.
ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
Structured plan for ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Biotech stocks showed mixed performance as Moderna advanced its Ebola vaccine efforts and Summit Therapeutics saw a surge on Phase 3 data. Meanwhile, Alignment Healthcare faced a downgrade, and Iovance Biotherapeutics remains a subject of analyst debate.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Congress & presentations
- PresentationPhase III data readout for a key trial in oncology (partnered with Summit Therapeutics)
- CongressBIO
Momentum
Proprietary activity score for Summit Therapeutics.
3 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Summit Therapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Summit Therapeutics?
-
Is Summit Therapeutics publicly traded?
-
What drugs does Summit Therapeutics develop or market?
-
What are the latest developments for Summit Therapeutics?
-
What therapeutic areas does Summit Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.